Antimicrobial susceptibility of Canadian isolates of Helicobacter pylori in Northeastern Ontario

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 26, Issue 3, 2015, Pages 137-144

  Nelson, F ^a   Ybazeta, Gustavo ^a   Chapman, Katrina ^a   Fraleigh, Nya L ^a   Letto, Rebecca ^a   Altman, Eleonora ^b   Diaz Mitoma, Francisco ^a  

^a Advanced Medical Research Institute of Canada   (Canada)

^b NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

Antimicrobial susceptibility; Helicobacter pylori; Northern ontario; Resistance

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CIPROFLOXACIN; CLARITHROMYCIN; GENOMIC DNA; LEVOFLOXACIN; METRONIDAZOLE; RNA 23S; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CANADA; DISK DIFFUSION; EPSILOMETER TEST; GENE; GENE MUTATION; GYRA GENE; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STOMACH BIOPSY;

EID: 84936864471     PISSN: 17129532     EISSN: 19181493     Source Type: Journal    
DOI: 10.1155/2015/853287     Document Type: Article

References (74)

1. Cheung J, Goodman K, Munday R, et al. Helicobacter pylori infection in Canada's arctic: Searching for the solutions. Can J Gastroenterol 2008;22:912-6.
2. Survival rates for stomach cancer by stage. Am Cancer Soc 2013. (Accessed July 15, 2014).
3. McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med 2010;362:1597-604.
4. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994;61:1-241.
5. Naja F, Kreiger N, Sullivan T. Helicobacter pylori infection in Ontario: Prevalence and risk factors. Can J Gastroenterol 2007;21:501-6.
6. Thomson AB, Barkun AN, Armstrong D, et al. The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: The Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study. Aliment Pharmacol Ther 2003;17:1481-91.
7. Graham DY, Adam E, Reddy GT, et al. Seroepidemiology of Helicobacter pylori infection in India. Comparison of developing and developed countries. Dig Dis Sci 1991;36:1084-8.
8. Graham DY, Malaty HM, Evans DG, Evans DJ Jr, Klein PD, Adam E. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterology 1991;100:1495-501.
9. Moayyedi P, Axon AT, Feltbower R, et al. Relation of adult lifestyle and socioeconomic factors to the prevalence of Helicobacter pylori infection. Int J Epidemiol 2002;31:624-31.
10. Woodward M, Morrison C, McColl K. An investigation into factors associated with Helicobacter pylori infection. J Clin Epidemiol 2000;53:175-81.
11. Olafsson S, Berstad A. Changes in food tolerance and lifestyle after eradication of Helicobacter pylori. Scand J Gastroenterol 2003;38:268-76.
12. Bernstein CN, McKeown I, Embil JM, et al. Seroprevalence of Helicobacter pylori, incidence of gastric cancer, and peptic ulcerassociated hospitalizations in a Canadian Indian population. Dig Dis Sci 1999;44:668-74.
13. Vakil N, Vaira D. Treatment for H. pylori infection: New challenges with antimicrobial resistance. J Clin Gastroenterol 2013;47:383-8.
14. Delaney BC, Qume M, Moayyedi P, et al. Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: Multicentre randomised controlled trial (MRC-CUBE trial). BMJ 2008;336:651-4.
15. Sharma VK, Howden CW. A national survey of primary care physicians' perceptions and practices related to Helicobacter pylori infection. J Clin Gastroenterol 2004;38:326-31.
16. Megraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007;20:280-322.
17. Bourke B, Ceponis P, Chiba N, et al. Canadian Helicobacter Study Group Consensus Conference: Update on the approach to Helicobacter pylori infection in children and adolescents - An evidence-based evaluation. Can J Gastroenterol 2005;19:399-408.
18. Hunt R, Fallone C, Veldhuyzan van Zanten S, et al. Canadian Helicobacter Study Group Consensus Conference: Update on the management of Helicobacter pylori-an evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for H pylori infection. Can J Gastroenterol 2004;18:547-54.
19. Cuadrado-Lavin A, Salcines-Caviedes JR, Carrascosa MF, et al. Antimicrobial susceptibility of Helicobacter pylori to six antibiotics currently used in Spain. J Antimicrob Chemother 2012;67:170-3.
20. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010;59:1143-53.
21. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection - The Maastricht IV/Florence Consensus Report. Gut 2012;61:646-64.
22. Heep M, Kist M, Strobel S, Beck D, Lehn N. Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis 2000;19:538-41.
23. Sycuro LK, Pincus Z, Gutierrez KD, et al. Peptidoglycan crosslinking relaxation promotes Helicobacter pylori's helical shape and stomach colonization. Cell 2010;141:822-33.
24. Attumi TA, Graham DY. High-dose extended-release lansoprazole (dexlansoprazole) and amoxicillin dual therapy for Helicobacter pylori infections. Helicobacter 2014;19:319-22.
25. Occhialini A, Urdaci M, Doucet-Populaire F, Bébéar CM, Lamouliatte H, Mégraud F. Macrolide resistance in Helicobacter pylori: Rapid detection of point mutations and assays of macrolide binding to ribosomes. Antimicrob Agents Chemother 1997;41:2724-8.
26. Versalovic J, Shortridge D, Kibler K, et al. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother 1996;40:477-80.
27. Gerrits MM, de Zoete MR, Arents NLA, Kuipers EJ, Kusters JG. 16S rRNA mutation-mediated tetracycline resistance in Helicobacter pylori. Antimicrob Agents Chemother 2002;46:2996-3000.
28. Trieber CA, Taylor DE. Mutations in the 16S rRNA genes of Helicobacter pylori mediate resistance to tetracycline. J Bacteriol 2002;184:2131-40.
29. Fallone CA. Epidemiology of the antibiotic resistance of Helicobacter pylori in Canada. Can J Gastroenterol 2000;14:879-82.
30. Best L, Haldane DJ, Veldhuyzen-Van-Zanten S. Helicobacter pylori antibiotic resistance in Canadian populations. Gastroenterology 2004;126:S1293.
31. Cheung J, Morse AL, Goodman KJ, et al. Prevalence of Helicobacter pylori and antibiotic resistance in an Aboriginal population in Canada's Arctic: Preliminary results from the Aklavik H. pylori Project. Gastroenterology 2009;136:A341.
32. Sethi A, Chaudhuri M, Kelly L, Hopman W. Prevalence of Helicobacter pylori in a First Nations population in northwestern Ontario. Can Fam Physician 2013;59:e182-7.
33. Taylor DE, Jiang Q, Fedorak RN. Antibiotic susceptibilities of Helicobacter pylori strains isolated in the Province of Alberta. Can J Gastroenterol 1998;12:295-8.
34. Hiratsuka K, Logan SM, Conlan JW, et al. Identification of a D-glycero-D-manno-heptosyltransferase gene from Helicobacter pylori. J Bacteriol 2005;187:5156-65.
35. Halebian S, Harris B, Finegold SM, Rolfe RD. Rapid method that aids in distinguishing Gram-positive from Gram-negative anaerobic bacteria. J Clin Microbiol 1981;13:444-8.
36. Garcia LS, ed. Clinical Microbiology Procedures Handbook, 3rd edn. Washington, DC: ASM Press, 2007.
37. Wang G, Wilson TJ, Jiang Q, Taylor DE. Spontaneous mutations that confer antibiotic resistance in Helicobacter pylori. Antimicrob Agents Chemother 2001;45:727-33.
38. Toledo H, López-Solís R. Tetracycline resistance in Chilean clinical isolates of Helicobacter pylori. J Antimicrob Chemother 2010;65:470-3.
39. EUCAST. Antimicrobial susceptibility testing. EUCAST disk diffusion method. (Accessed April 2013).
40. Boyanova L, Stancheva I, Spassova Z, Katzarov N, Mitov I, Koumanova R. Primary and combined resistance to four antimicrobial agents in Helicobacter pylori in Sofia, Bulgaria. J Med Microbiol 2000;49:415-8.
41. Lee CC, Lee VWY, Chan FKL, Ling TKW. Levofloxacin-resistant Helicobacter pylori in Hong Kong. Chemotherapy 2008;54:50-3.
42. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 4.0, 2014.
43. Mégraud F. H pylori antibiotic resistance: Prevalence, importance, and advances in testing. Gut 2004;53:1374-84.
44. Camacho C, Coulouris G, Avagyan V, et al. BLAST+: Architecture and applications. BMC Bioinformatics 2009;10:421.
45. Bonfield JK, Whitwham A. Gap5 - editing the billion fragment sequence assembly. Bioinformatics 2010;26:1699-703.
46. Gouy M, Guindon S, Gascuel O. SeaView version 4: A multiplatform graphical user interface for sequence alignment and phylogenetic tree building. Mol Biol Evol 2010;27:221-4.
47. Edgar RC. MUSCLE: Multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 2004;32:1792-7.
48. Fedorak R, Archambault A, Flamm R, Osato M, Stamler D. Antimicrobial susceptibility of H. pylori in Canada to three key antibiotics: Metronidazole, clarithromycin and amoxicillin. Gastroenterology 1997;112:A115.
49. Smith C, Perkins J, Tompkins DS. Comparison of Etest and disc diffusion for detection of antibiotic resistance in Helicobacter pylori. PHLS Microbiol Dig 1997;14:21-3.
50. Weiss K, Laverdière M, Restieri C. Comparison of activity of 10 antibiotics against clinical strains of Helicobacter pylori by three different techniques. Can J Gastroenterol 1998;12:181-5.
51. Osato MS. Antimicrobial susceptibility testing for Helicobacter pylori: Sensitivity test results and their clinical relevance. Curr Pharm Des 2000;6:1545-55.
52. DeCross AJ, Marshall BJ, McCallum RW, Hoffman SR, Barrett LJ, Guerrant RL. Metronidazole susceptibility testing for Helicobacter pylori: Comparison of disk, broth, and agar dilution methods and their clinical relevance. J Clin Microbiol 1993;31:1971-4.
53. Cederbrant G, Kahlmeter G, Ljungh A. The E test for antimicrobial susceptibility testing of Helicobacter pylori. J Antimicrob Chemother 1993;31:65-71.
54. Mishra KK, Srivastava S, Garg A, Ayyagari A. Antibiotic susceptibility of Helicobacter pylori clinical isolates: Comparative evaluation of disk-diffusion and E-test methods. Curr Microbiol 2006;53:329-34.
55. Falsafi T, Mobasheri F, Nariman F, Najafi M. Susceptibilities to different antibiotics of Helicobacter pylori strains isolated from patients at the pediatric medical center of Tehran, Iran. J Clin Microbiol 2004;42:387-9.
56. Ozbey G, Bahcecioglu IH, Acik MN. Resistance rates to various antimicrobial agents of Helicobacter pylori isolates in Eastern Turkey. Int J Mol Clin Microbiol 2012;2:148-52.
57. Moore RA, Beckthold B, Wong S, Kureishi A, Bryan LE. Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori. Antimicrob Agents Chemother 1995;39:107-11.
58. Paul R, Postius S, Melchers K, Schäfer KP. Mutations of the Helicobacter pylori genes rdxA and pbp1 cause resistance against metronidazole and amoxicillin. Antimicrob Agents Chemother 2001;45:962-5.
59. Mendz GL, Mégraud F. Is the molecular basis of metronidazole resistance in microaerophilic organisms understood? Trends Microbiol 2002;10:370-5.
60. Chisholm SA, Owen RJ. Mutations in Helicobacter pylori rdxA gene sequences may not contribute to metronidazole resistance. J Antimicrob Chemother 2003;51:995-9.
61. Marais A, Bilardi C, Cantet F, Mendz GL, Mégraud F. Characterization of the genes rdxA and frxA involved in metronidazole resistance in Helicobacter pylori. Res Microbiol 2003;154:137-44.
62. Bereswill S, Krainick C, Stähler F, Herrmann L, Kist M. Analysis of the rdxA gene in high-level metronidazole-resistant clinical isolates confirms a limited use of rdxA mutations as a marker for prediction of metronidazole resistance in Helicobacter pylori. FEMS Immunol Med Microbiol 2003;36:193-8.
63. Choi SS, Chivers PT, Berg DE. Point mutations in Helicobacter pylori's fur regulatory gene that alter resistance to metronidazole, a prodrug activated by chemical reduction. PLoS One 2011;6:e18236.
64. Kim BJ, Kim JG. Substitutions in penicillin-binding protein 1 in amoxicillin-resistant Helicobacter pylori strains isolated from Korean patients. Gut Liver 2013;7:655-60.
65. Matteo MJ, Granados G, Olmos M, Wonaga A, Catalano M. Helicobacter pylori amoxicillin heteroresistance due to point mutations in PBP-1A in isogenic isolates. J Antimicrob Chemother 2008;61:474-7.
66. Kwon DH, Dore MP, Kim JJ, et al. High-level β-lactam resistance associated with acquired multidrug resistance in Helicobacter pylori. Antimicrob Agents Chemother 2003;47:2169-78.
67. Co E-MA, Schiller NL. Resistance mechanisms in an in vitroselected amoxicillin-resistant strain of Helicobacter pylori. Antimicrob Agents Chemother 2006;50:4174-6.
68. Goodwin CS, Marshall BJ, Blincow ED, Wilson DH, Blackbourn S, Phillips M. Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: Clinical and in vitro studies. J Clin Pathol 1988;41:207-10.
69. Tompkins DS, Perkin J, Smith C. Failed treatment of Helicobacter pylori infection associated with resistance to clarithromycin. Helicobacter 1997;2:185-7.
70. Fantry GT, Zheng QX, Darwin PE, Rosenstein AH, James SP. Mixed infection with cagA-positive and cagA-negative strains of Helicobacter pylori. Helicobacter 1996;1:98-106.
71. Engstrand L, Nguyen AM, Graham DY, el-Zaatari FA. Reverse transcription and polymerase chain reaction amplification of rRNA for detection of Helicobacter species. J Clin Microbiol 1992;30:2295-301.
72. Tummuru MK, Cover TL, Blaser MJ. Cloning and expression of a high-molecular-mass major antigen of Helicobacter pylori: Evidence of linkage to cytotoxin production. Infect Immun 1993;61:1799-809.
73. Labigne A, Cussac V, Courcoux P. Shuttle cloning and nucleotide sequences of Helicobacter pylori genes responsible for urease activity. J Bacteriol 1991;173:1920-31.
74. Clayton C, Kleanthous K, Tabaqchali S. Detection and identification of Helicobacter pylori by the polymerase chain reaction. J Clin Pathol 1991;44:515-6.